Yubo Wang Rui Han Mengxiao Zhu Tingting He Yong He
10.3389/fonc.2022.875313
Front Oncol
2022 Apr 21;12:875313.
nsclc t790m-cis-g796s brigatinib cetuximab osimertinib resistance
CC BY
https://pubmed.ncbi.nlm.nih.gov/35530305/
Case Reports
PMC9071300
35530305
Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib
2022